| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1376399 | Bioorganic & Medicinal Chemistry Letters | 2008 | 4 Pages |
Abstract
Novel phosphoramidates of acyclovir have been prepared and evaluated in vitro against acyclovir-sensitive and -resistant herpes simplex virus (HSV) types 1 and 2 and varicella-zoster virus (VZV). Unlike the parent nucleoside these novel phosphate prodrugs retain antiviral potency versus the ACV-resistant virus strain, suggesting an efficient bypass of the viral thymidine kinase.
Graphical abstractLow or sub-μM versus HSV-1 and -2 and VZV. Retain full activity versus thymidine kinase mutants proving intracellular phosphate delivery.Figure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Christopher McGuigan, Marco Derudas, Joachim J. Bugert, Graciela Andrei, Robert Snoeck, Jan Balzarini,